In other words, someone who was overweight (a body mass index between 27 and 30) at the start of the study tended to see a similar reduction in heart disease risk as compared to someone with the highest level of obesity (a BMI over 40)
A: Because all three sit in the obesity and metabolic medicine space
Some countries may have restrictions on importing compounded (as opposed to commercially manufactured) medications
In summary, the pronounced disparity in DEG counts between semaglutide and tirzepatide is best understood as the outcome of a multifactorial interplay involving (i) distinct pharmacological mechanisms and receptor selectivity, (ii) non-equivalent dosing and consequent differences in transcriptomic breadth, and (iii) biological as well as technical variability, rather than a straightforward difference in therapeutic potency
Tirzepatide, used in Zepbound and Mounjaro, targets both the GLP-1 and the GIP receptor agonist, while semaglutide, found in Wegovy and Ozempic, mimics only the GLP-1 receptor agonist, a type of hormone in the body that impacts everything from the brain to muscle to the pancreas, stomach and liver
In a study extension to 104 weeks, some achieved up to a 30.3% weight loss
